Research & Education

IASLC European Webinar Series - 2015/2016 - WHO Classification of Tumours of the Lung

Thursday, October 8, 2015 - 6 p.m. BST - Recording Available
 Andrew Nicholson

Professor Andrew G Nicholson, FRCPath, DRC
Department of Histopathology
Royal Brompton And Harefield Hospitals NHS Foundation Trust
Imperial College School of Medicine, London, UK

Name of Reviewer(s): 

              

Fred Hirsch, MD, PhD –Speakers Bureau/Advisory Board: Astrazeneca, Genentech, BMS, Lilly and Abbvie.

Name of Planner(s): 

 

    Deb Whippen-Nothing to Disclose

Name of Activity: 

 

WHO Classification of Tumors of the Lung

Date of Activity:

 

10/08/2015

Faculty/Speaker(s):

Financial DISCLOSURES

 

Professor Andrew G Nicholson, FRCPath, DRC-Speaker

Speaker: Astrazeneca, Eli Lilly.

Consultant: Merck, Boehringer-Ingelhem, Pfeizer, Novartis, Astrazeneca, Bristol-Meyers Squibb

Franco Foti – Moderator-Nothing to Disclose

Type of Activity: 

 Live Course

  Internet Live Course (Webinar)XXXX

 Internet Enduring Material

Are there Commercial Supporters for this activity?

       Yes     

If yes, please list: Supported by an unrestricted grant from Genentech, Bristol-Meyer Squibb, and Celgene.

In this program Professor Nicholson will describe the important changes in the 2015 WHO classification of lung tumours, reflecting the numerous advances in tumour genetics and therapy over the past decade. In particular, classification of small biopsies and cytology is provided within the classification for the first time, with emphasis on integration of molecular testing. Changes to classification of other major tumour types will also be presented and discussed, in particular adenocarcinomas where there have been significant revisions since 2004.

After viewing this program attendees will:

  1. Articulate how to handle small biopsy and cytology samples, in particular in relation to approaching molecular testing, and how to classify lung cancers consistently.
  2. Define the clinical significance of variants and histologic patterns of adenocarcinoma, in particular adenocarcinoma in situ, minimally invasive adenocarcinoma and pattern predominance.
  3. Recognize the increasing importance of immunohistochemistry in the diagnosis of lung tumours
  4. Illustrate the implications of the 2015 WHO classification on tumour staging.

This CME live webinar series is designed to meet the educational needs of healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists and advanced practice nurses and physicians' assistants.

 

CME INFORMATION:

Financial/Commercial Relationships DISCLOSURES

A Conflict of Interest (COI) is created and exists when individuals in a position to control the content of CME, or their spouses/partners, that have a relevant personal financial relationship within the past 12 months with a commercial interest that produces, markets, re-sells, or distributes health care goods or services consumed by, or used, on patients that benefits the individual in any financial amount and therefore, may bias their opinions and teachings. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or any other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research and clinical trials), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities for which remuneration is received or expected. 

 This IASLC CME educational activity was planned and developed to: uphold academic standards to ensure balance, independence, objectivity, and scientific rigor; adhere to requirements to protect health information under the Health Insurance Portability and Accountability Act of 1996 (HIPAA); and, include a mechanism to inform learners when unapproved or unlabeled uses of therapeutic products or agents are discussed or referenced.

IASLC CME assures that the planners/reviewers/authors/faculty/moderators/peer reviewers et. al. conflicts of interest  were identified, reviewed and resolved from all individuals involved in the development  or able to influence and control the content of this CME activity; IASLC CME assures that disclosure is given prior to an educational activity being delivered to learners.  Any individual who failed or refused to disclose relevant financial relationships was disqualified from this CME activity and removed from any of IASLC CME activity presentation.

All commercial relationships and conflicts of interest that are identified are thoroughly vetted by IASLC Ethics Committee, CME Subcommittee, and Independent reviewer. COI will be evaluated by the Board of Directors of the IASLC for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. IASLC CME is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial entity.

CREDIT STATEMENT

IASLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

IASLC CME designates this Internet Live Course activity for a maximum of 1 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

GOAL & PURPOSE

This activity will describe the important changes in the 2015 WHO classification of lung tumours, reflecting the numerous advances in tumour genetics and therapy over the past decade. In particular, classification of small biopsies and cytology is provided within the classification for the first time, with emphasis on integration of molecular testing. Changes to classification of other major tumour types will also be presented and discussed, in particular adenocarcinomas where there have been significant revisions since 2004.

TARGET AUDIENCE

This CME live webinar series is designed to meet the educational needs of healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists and advanced practice nurses and physicians' assistants.

DISCLAMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Thank you for your participation.

DOWNLOAD RECORDING

IASLC Financial/Commercial Relationships and Conflicts of Interest Policy

IASLC Honoraria Policy

IASLC Commercial Support Agreement (LOA)

If you are interested in obtaining the CME Credits for these sessions you must indicate this when you register for the program. CME credit is only available to attendees of the live webinar.

Location Local time Time zone UTC offset
New York (U.S.A. - New York) Thursday, October 8, 2015 at 1:00:00 PM EDT UTC-4 hours
London (United Kingdom) Thursday, October 8, 2015 at 6:00:00 PM BST UTC+1 hour
Paris (France) Thursday, October 8, 2015 at 7:00:00 PM CEST UTC+2 hours
Glasgow (United Kingdom) Thursday, October 8, 2015 at 7:00:00 PM BST UTC+2 hours 
Rome (Italy) Thursday, October 8, 2015 at 7:00:00 PM CEST UTC+2 hours
Brussels (Belgium) Thursday, October 8, 2015 at 7:00:00 PM CEST UTC+2 hours
Moscow (Russia) Thursday, October 8, 2015 at 8:00:00 PM MSK UTC+3 hours
Amsterdam (Netherlands) Thursday, October 8, 2015 at 7:00:00 PM CEST UTC+2 hours
Dublin (Ireland) Thursday, October 8, 2015 at 6:00:00 PM IST UTC+1 hour
Los Angeles (U.S.A.) Thursday, October 8 2015 at 10:00:00 AM PDT UTC-7 hours
Corresponding UTC (GMT) Thursday, October 8, 2015 at 5:00:00 PM     

How to use the Time Zone Converter